Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX, gives an overview of treatments targeting CD123 in patients with diverse myeloid malignancies. Dr Pemmaraju discusses the approval of tagraxofusp, a CD123-directed immunotherapy approved for the treatment of blastic plasmacytoid dendritic cell neoplasm, and it’s expansion into other hematologic malignancies, as well as commenting on novel CD123-tagergting agents, such as IMGN632, and combinatorial approaches. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.